The FDA on November 9, 2026 required all GLP-1 drug labels to add a Warnings and Precautions notice about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden permanent blindness. Based on 126 clinical trials, the FDA estimated 6.4 NAION cases per 100,000 person-years among GLP-1 users vs. 3.8 in comparators—a ~1.7-fold relative risk—though causality has not been established.
FDA GLP-1 label change
- ▪The FDA's NAION risk estimate for GLP-1 drugs was based on an analysis of 126 clinical trials
- ▪The FDA's decision to update GLP-1 drug labels followed studies suggesting an association between GLP-1 drugs and NAION, although causality has not been established
- ▪On November 9, 2026, the FDA announced that GLP-1 drug labels would be required to include information in the Warnings and Precautions section about the potential increased risk for nonarteritic anterior ischemic optic neuropathy (NAION)
NAION risk statistics
- ▪The baseline risk for NAION in the fellow eye is approximately 15% within 3–5 years after a first NAION event
- ▪NAION is the most common acute unilateral optic neuropathy in older adults and presents as acute, unilateral painless vision loss, usually with an altitudinal visual field defect
- ▪The FDA said the absolute difference in NAION rates between GLP-1 drug users and comparators is 2.6 additional cases per 100,000 person-years
- ▪The FDA said the difference in NAION rates between GLP-1 drug users and comparators represents an approximately 1.7-fold relative risk
- ▪The FDA estimated 6.4 cases of NAION per 100,000 person-years among users of GLP-1 drugs, compared with 3.8 cases per 100,000 person-years among patients receiving placebo or other glucose-lowering medications
Proposed biological mechanisms
- ▪The NAION risk associated with GLP-1 drugs does not appear to be dose dependent, suggesting the events are idiosyncratic rather than toxic
- ▪NAION is thought to result from hypoperfusion of the optic nerve rather than a blood clot or embolus, and is associated with a small cup-to-disc ratio (a 'crowded' optic disc)
- ▪One proposed mechanism linking GLP-1 drugs to NAION is local autoregulatory failure at the optic nerve head triggered by tighter metabolic control
Patient risk factors
- ▪Traditional risk factors for NAION include hypertension, diabetes, hyperlipidemia, and obstructive sleep apnea — the same conditions that often accompany obesity and diabetes for which GLP-1 drugs are prescribed
- ▪Most evidence linking GLP-1 drugs to NAION comes from patients with type 2 diabetes, but the FDA's November 9 label change also covers GLP-1 drugs used for obesity
- ▪Patients who have already experienced NAION in one eye face a higher baseline risk for NAION in the fellow eye and warrant a different risk-benefit discussion regarding GLP-1 continuation
Clinical management guidance
- ▪Andrew G. Lee, MD, is chair of the Blanton Eye Institute at Houston Methodist Hospital and professor of ophthalmology, neurology, and neurosurgery at Weill Cornell Medicine in New York City
- ▪If a patient on a GLP-1 drug reports vision loss, an eye examination is needed to determine whether the cause is NAION or another condition such as retinal detachment or retinal vascular occlusion
- ▪Prescribing physicians should inform patients about the GLP-1-associated NAION risk and advise them to seek an eye examination if they experience vision loss
- ▪Ophthalmologists should ask patients who develop NAION whether they are taking GLP-1 medications, because patients might not volunteer that information
- ▪The decision to continue or discontinue a GLP-1 drug after a NAION diagnosis should be made jointly by the patient, eye doctor, and prescribing physician on an individualized basis
Story comments
Loading comments…